A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

导出原文传递

翻译打印收藏纠错

作者： de Jong, Jan ^[1] ; Hellemans, Peter ^[2] ; De Wilde, Severijn ^[3] ; Patricia, Daniel ^[4] ; Masterson, Tara ^[5] ; Manikhas, Georgii ^[6] ; Myasnikov, Alexander ^[7] ; Osmanov, Dzhelil ^[8] ; Cordoba, Raul ^[9] ; Panizo, Carlos ^[10] ; de Zwart, Loeckie ; Snoeys, Jan ; Chauhan, Vijay ; Jiao, James ; Sukbuntherng, Juthamas ; Ouellet, Daniele

作者单位： Janssen Res & Dev LLC, 3210 Merryfield Row, San Diego, CA 92121 USA ^[1] Univ Clin Navarra, Pamplona, Spain ^[2] NN Blokhin Russian Acad Med Sci, Moscow, Russia ^[3] St Petersburg City Oncol Hosp, St Petersburg, Russia ^[4] Janssen Res & Dev, Spring House, PA USA ^[5] Janssen Res & Dev, Beerse, Belgium ^[6] Janssen Res & Dev, Raritan, NJ USA ^[7] Pharmacyclics LLC, Sunnyvale, CA USA ^[8] Baranov Republican Hosp, Petrozavodsk, Russia ^[9] Univ Hosp Fdn Jimenez Diaz, START Madrid, Hlth Res Inst IIS FJD, Madrid, Spain ^[10]

关键词 Erythromycin CYP3A ibrutinib pharmacokinetics voriconazole

发布时间 2020-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交